Stelo By Dexcom First Glucose Biosensor To Be Cleared By FDA As Over-The-Counter
Portfolio Pulse from Benzinga Newsdesk
The FDA has cleared Stelo, a glucose biosensor by Dexcom, for over-the-counter use in the US. It's designed for individuals 18 and older with Type 2 diabetes not on insulin therapy. Stelo, a small wearable sensor, provides glucose insights directly to a smartphone and is set to be available in summer 2024.
March 05, 2024 | 9:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dexcom's Stelo, a new glucose biosensor, has been cleared by the FDA for over-the-counter sales in the US, targeting individuals with Type 2 diabetes not using insulin. This expands Dexcom's product line and could increase its market share.
The FDA clearance of Stelo as an over-the-counter product represents a significant expansion of Dexcom's product offerings and market potential. Given the large and growing market for diabetes care, particularly Type 2 diabetes, this approval could lead to increased sales and market share for Dexcom. The product's ease of use and direct smartphone connectivity are likely to appeal to a broad segment of users, potentially boosting Dexcom's revenue and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100